ETCapital

ET Capital is an early-stage venture capital firm located in Cambridge, United Kingdom, a prominent hub for technology. Founded in 1992, the firm specializes in investing in growth-stage companies across various sectors, including life sciences, healthcare, materials, and technology. Since its inception, ET Capital has supported numerous entrepreneurs in their efforts to develop successful businesses, resulting in three companies going public and eight achieving profitable exits. The firm focuses on nurturing innovative ventures, contributing to the dynamic ecosystem of the UK's technology landscape.

Martin Rigby

Managing Director

6 past transactions

Materials Nexus

Seed Round in 2023
Materials Nexus is a deep-tech company focused on advancing sustainable materials through an innovative material modeling platform. By automating quantum calculations, the company enhances the accuracy of material research at scale, thereby facilitating the development of green materials that contribute to net-zero emissions. Utilizing insights from quantum mechanics and artificial intelligence, Materials Nexus aims to reduce greenhouse gas emissions in the materials sector, providing clients with access to sustainable building solutions. Through its efforts, the company seeks to accelerate the transition to environmentally friendly materials and support the global shift toward sustainability.

Phico Therapeutics

Venture Round in 2009
Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Phico Therapeutics

Venture Round in 2006
Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Bango

Venture Round in 2002
Bango plc is a technology company that specializes in facilitating mobile payments and marketing for products and services aimed at mobile phone users. The company operates through two main segments: End User Activity and Data Activity. Its flagship offering, the Bango Payment Platform, connects app stores and content providers directly with mobile operators globally, enabling seamless billing for digital content such as apps, music, and games. Additionally, Bango Marketplace allows developers to target specific customer audiences, while Bango Resale supports merchants in acquiring and retaining customers through global partnerships. The company also provides Audiens, a mobile data exchange platform. Established in 1999 and headquartered in Cambridge, UK, Bango serves markets in the United Kingdom, European Union, the United States, Canada, and other regions worldwide.

Cyan Technology

Series A in 2000
Cyan Technology Ltd develops and markets ultra low power RISC microcontroller with configurable peripherals.

Plastic Logic

Seed Round in 2000
Plastic Logic Ltd specializes in the development and manufacturing of plastic electronics, particularly flexible displays. The company produces both color and monochrome electrophoretic displays, which are utilized in a variety of applications including smartphones, e-readers, tablets, signage, wristwatches, and automotive displays. With a focus on lightweight, shatterproof, and energy-efficient technology, Plastic Logic's products offer significant advantages over traditional screens. The company's manufacturing capabilities are centered in Dresden, Germany, where it operates a pioneering facility dedicated to organic electronics. It serves a diverse clientele, including OEMs, system integrators, and device manufacturers in multiple countries, including the United Kingdom, Germany, and Russia. Additionally, Plastic Logic collaborates with third-party companies through an open pilot line, providing expertise in the industrialization of flexible electronics. Founded in 2000 and based in Cambridge, Plastic Logic continues to innovate in the field of flexible display technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.